Bluebird shares leap after gene therapy seen as cure for blood disorder

(Reuters) - Shares of drug developer bluebird bio Inc shot up on Tuesday, after the company presented data that showed a cure for beta-thalassemia is within reach, prompting several brokerages to raise their price targets on the stock. The Cambridge, Massachusetts-based company's stock jumped about 72 percent to $84.00 in early trade. One of the most common genetic blood disorders, beta-thalassemia, is characterized by a reduction in hemoglobin, and requires patients to take lifelong transfusions. If left untreated, those affected often die in their forties. ...



via Health News Headlines - Yahoo News http://ift.tt/1Gf2z3s